Maxim Surgical Achieves FDA Clearance for New Spinal Implants Made of Solvay’s Zeniva® PEEK
ALPHARETTA, Ga., May 7, 2013– Maxim Surgical, a new designer and manufacturer of spinal implants, has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new MaxFuse-C™ cervical interbody fusion system made of Zeniva® polyetheretherketone (PEEK) rods from Solvay Specialty Polymers. Zeniva® PEEK – part of Solvay’s line of Solviva® Biomaterials – has a modulus very close to that of bone plus excellent toughness and fatigue resistance. The FDA clearance was based in part on Solvay’s well-developed master access file for Zeniva® PEEK.
The cervical interbody fusion system made from Zeniva® PEEK rod is hollow so that bone can grow through the device, fusing the adjacent bony surfaces of the vertebrae. The cervical spacer for the spinal fusion market is Maxim’s first orthopedic implant.
Zeniva® PEEK offers numerous advantages over metals such as titanium for spinal implants. The material offers many important benefits including biocompatibility, chemical inertness, and a modulus of elasticity that is close to that of bone. Based on biocompatibility testing, Zeniva® PEEK demonstrates no evidence of cytotoxicity, sensitization, irritation, or acute systemic toxicity, and meets the ASTM F2026 standard. It also boasts high strength and stiffness and has radiolucent properties which enable x-ray procedures without interference.
The MaxFuse-C™ cervical interbody fusion system is machined from 16-mm and 20-mm diameter Zeniva® PEEK rods. It is available in two footprints – 15-mm x13-mm and 17-mm x 14-mm in both neutral and six degree lordotic options – offering surgeons flexibility in meeting different patient anatomies. The system also provides a large graft window which facilitates a bigger graft volume for fusion. Maxim offers an easy-to-use single tray system which includes simplified instrumentation for all of their available implant options. Maxim plans to explore the future use of Zeniva® PEEK in a range of other spinal fusion products.
“We’re excited about the commercial success of Zeniva® PEEK in the orthopedic implantable market,” said Shawn Shorrock, global healthcare market manager for Solvay Specialty Polymers. “The ongoing acceptance of Zeniva® PEEK has validated our approach to the orthopedic implant market and we’re encouraged by the momentum we’ve generated.”
The manufacturing site for Zeniva® PEEK and other Solviva® Biomaterials in Alpharetta, Ga., is ISO 13485 registered and the relevant aspects of current Good Manufacturing Practices are also applied. Solvay’s biomaterial manufacturing processes are carefully validated and enhanced controls provide product traceability. In addition, all materials are tested in an ISO 17025 accredited lab.
In addition to Zeniva® PEEK, Solvay’s Solviva® Biomaterials line includes Veriva® polyphenylsulfone (PPSU), which provides unsurpassed toughness combined with transparency and excellent chemical resistance; Eviva® polysulfone (PSU), which offers toughness in a strong, transparent polymer; and Proniva® self-reinforced polyphenylene (SRP), one of the world’s stiffest and strongest unreinforced thermoplastics that offers exceptional chemical resistance and hardness. These sterilizable products are available in injection molding and extrusion grades as well as rods and plates for machined components.
About Maxim Surgical
Maxim Surgical, based in Richardson, Texas, is a privately held medical device company which is focused on the development of innovative solutions for the spinal fusion device market. Founded in 2011, the company’s primary mission is to provide surgeons and their patients with high-quality medical implants with a value approach. Maxim has a close partnership with key industry leaders and has a world-class development team to manufacture leading-edge implant products at a cost savings for the surgical spinal fusion market. Learn more at www.maximsurgical.com.As an international chemical group, SOLVAY assists industries in finding and implementing ever more responsible and value-creating solutions. Solvay generates 90% of its net sales in activities where it is among the world's top three players. It serves many markets, varying from energy and the environment to automotive and aerospace or electricity and electronics, with one goal: to raise the performance of its clients and improve society's quality of life. The group is headquartered in Brussels, employs about 29,400 people in 56 countries and generated 9.9 billion euros in net sales in 2013. Solvay SA is listed as SOLB.BE on NYSE Euronext in Brussels and Paris (Bloomberg: SOLB:BB - Reuters: SOLB.BR).